Natural Killer-cell Therapy for Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study investigates an innovative treatment for relapsed or refractory acute myeloid
leukemia exploiting administration of ex vivo-generated allogeneic natural killer (NK) cells
with preceding non-myeloablative conditioning chemotherapy with or without subsequent in vivo
IL-2 cytokine support.